Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TYMP | P19971 | 3/20 | 0.50 |
| ▸ | TK1 | P04183 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TK2 | O00142 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4194710 | 0.85 | MAPK1 (0.56) | MAPK1HPGDTYMPTK1TK2 | |
| SCHEMBL20743084 | 0.82 | TK2 (0.55) | MAPK1HPGDTYMPTK1TK2 | |
| SCHEMBL2183944 | 0.82 | MAPK1 (0.61) | MAPK1HPGDTYMPTK1ALDH1A1 | |
| SCHEMBL6471981 | 0.81 | MAPK1 (0.44) | MAPK1HPGDTYMPTK1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL4194711 | 0.80 | MAPK1 (0.59) | MAPK1HPGDTYMPTK1ALDH1A1 | |
| SCHEMBL27708058 | 0.80 | MAPK1 (0.59) | MAPK1HPGDTYMPTK1ALDH1A1 | |
| SCHEMBL26034737 | 0.80 | MAPK1 (0.59) | MAPK1HPGDTYMPTK1 | |
| SCHEMBL15110503 | 0.80 | TK2 (0.60) | MAPK1HPGDTYMPTK1TK2 | |
| SCHEMBL19181903 | 0.79 | TK1 (0.63) | MAPK1TK1TK2 | |
| SCHEMBL4118603 | 0.78 | MAPK1 (0.57) | MAPK1HPGDTYMPTK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070139-A | Composition for preventing or treating bladder cancer | 基因特力株式会社 | 2026-05-19 | — | — | CN | disclosed |
| EP-4731764-A2 | DOUBLE STRANDED RNA TARGETING PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) AND METHODS OF USE THEREOF | Sanegene Bio USA Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250382616-A1 | SMALL INTERFERING RNA TARGETING CFB AND USES THEREOF | SANEGENE BIO USA INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12497642-B2 | Incorporation of unnatural nucleotides and methods of use in vivo thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4659246-A1 | ELECTROCHEMICAL SYNTHESIS WITH REDOX STABLE NUCLEOTIDES | Atlas Data Storage, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250368986-A1 | ELECTROCHEMICAL SYNTHESIS WITH REDOX STABLE NUCLEOTIDES | ATLAS DATA STORAGE INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12281137-B2 | Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250059540-A1 | DOUBLE STRANDED RNA TARGETING ANGIOPOIETIN-LIKE 3 (ANGPTL-3) AND METHODS OF USE THEREOF | SANEGENE BIO USA INC. | 2025-02-20 | — | — | US | disclosed |
| US-20250027089-A1 | DOUBLE STRANDED RNA TARGETING PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) AND METHODS OF USE THEREOF | SANEGENE BIO USA INC. | 2025-01-23 | — | — | US | disclosed |
| CN-113597433-B | GPRC5D chimeric antigen receptors and cells expressing these receptors | 詹森生物科技公司 | 2024-12-27 | — | — | CN | disclosed |
| US-6033855-A | Genes encoding caspase recruitment domain polypeptides | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| WO-2000000633-A1 | OCT1p, A PROTEIN HAVING HOMOLOGY TO THE ORGANIC AND SUGAR TRANSPORTER FAMILY OF PROTEINS, AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-01-06 | — | — | WO | disclosed |
| US-5942398-A | A NUCLEOTIDE SEQUENCE THAT CODES FOR A GLUCOSE TRANSPORT PROTEIN; DIAGNOSIS AND TREATMENT OF DISORDERS ASSOCIATED WITH HEXOSE TRANSPORT | MILLENNIUM PHARMACEUTICALS, INC. (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1999024610-A1 | NOVEL GENES ENCODING TRANSPORTER-LIKE MOLECULES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| WO-1998005352-A1 | HYPOTHALAMUS-SPECIFIC POLYPEPTIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1996008559-A1 | GLYCOSAMINOGLYCAN-DEGRADING ENZYME INHIBITION AND RESULTANT DISEASE THERAPIES | CARDIAC CRC NOMINEES PTY. LTD. (AU) | 1996-03-21 | — | — | WO | disclosed |
| WO-1994022864-A1 | ACYCLIC NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE SEQUENCES CONTAINING THEM | STERLING WINTHROP INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0537299-A1 | OLIGONUCLEOTIDE-TRANSPORT AGENT DISULFIDE CONJUGATES | GILEAD SCIENCES, INC. (US) | 1993-04-21 | — | — | EP | disclosed |
| EP-0537299-A4 | OLIGONUCLEOTIDE-TRANSPORT AGENT DISULFIDE CONJUGATES. | GILEAD SCIENCES INC (US) | 1993-02-05 | — | — | EP | disclosed |
| WO-1991014696-A1 | OLIGONUCLEOTIDE-TRANSPORT AGENT DISULFIDE CONJUGATES | GILEAD SCIENCES, INC. (US) | 1991-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497642-B2 | Incorporation of unnatural nucleotides and methods of use in vivo thereof | NUDT1, DNTT, RNGTT | MAPK1 4808/4885HPGD 1782/4885TYMP 74/4885 |
| US-12281137-B2 | Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides | RNGTT, POLM, POLRMT | MAPK1 4395/4885HPGD 3220/4885TYMP 49/4885 |
| US-20250382616-A1 | SMALL INTERFERING RNA TARGETING CFB AND USES THEREOF | CFB, CFTR, RNASE1 | MAPK1 4698/4885HPGD 4680/4885TYMP 3427/4885 |
| US-20250027089-A1 | DOUBLE STRANDED RNA TARGETING PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | MAPK1 4194/4885HPGD 4502/4885TYMP 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.